Charles Schwab Investment Management Inc Zentalis Pharmaceuticals, Inc. Transaction History
Charles Schwab Investment Management Inc
- $521 Billion
- Q1 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 486,499 shares of ZNTL stock, worth $656,773. This represents 0.0% of its overall portfolio holdings.
Number of Shares
486,499
Previous 497,362
2.18%
Holding current value
$656,773
Previous $1.51 Million
48.71%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding ZNTL
# of Institutions
139Shares Held
61.1MCall Options Held
7.9KPut Options Held
42.5K-
Matrix Capital Management Company, LP Waltham, MA14MShares$18.8 Million6.94% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$6.51 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.26MShares$4.4 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.07MShares$4.14 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.67MShares$3.61 Million0.01% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $76.9M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...